Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Corrigendum: Designer Leptin Receptor Antagonist Allo-aca Inhibits VEGF Effects in Ophthalmic Neoangiogenesis Models.

Coroniti R, Farjo R, Nuno DJ, Otvos L, Scolaro L, Surmacz E.

Front Mol Biosci. 2016 Nov 18;3:75. eCollection 2016.

2.

Designer Leptin Receptor Antagonist Allo-aca Inhibits VEGF Effects in Ophthalmic Neoangiogenesis Models.

Coroniti R, Fario R, Nuno DJ, Otvos L, Scolaro L, Surmacz E.

Front Mol Biosci. 2016 Oct 13;3:67. eCollection 2016. Erratum in: Front Mol Biosci. 2016 Nov 18;3:75.

3.

Molecular targeting of obesity pathways in cancer.

Surmacz E, Otvos L.

Horm Mol Biol Clin Investig. 2015 May;22(2):53-62. doi: 10.1515/hmbci-2015-0007. Review.

PMID:
25879324
4.

Optimization of adiponectin-derived peptides for inhibition of cancer cell growth and signaling.

Otvos L Jr, Kovalszky I, Olah J, Coroniti R, Knappe D, Nollmann FI, Hoffmann R, Wade JD, Lovas S, Surmacz E.

Biopolymers. 2015 May;104(3):156-66. doi: 10.1002/bip.22627.

PMID:
25683126
5.

Development of second generation peptides modulating cellular adiponectin receptor responses.

Otvos L Jr, Knappe D, Hoffmann R, Kovalszky I, Olah J, Hewitson TD, Stawikowska R, Stawikowski M, Cudic P, Lin F, Wade JD, Surmacz E, Lovas S.

Front Chem. 2014 Oct 17;2:93. doi: 10.3389/fchem.2014.00093. eCollection 2014.

6.

Designer adiponectin receptor agonist stabilizes metabolic function and prevents brain injury caused by HIV protease inhibitors.

Pepping JK, Otvos L Jr, Surmacz E, Gupta S, Keller JN, Bruce-Keller AJ.

J Neuroimmune Pharmacol. 2014 Jun;9(3):388-98. doi: 10.1007/s11481-014-9529-1. Epub 2014 Feb 23.

7.

The designer leptin antagonist peptide Allo-aca compensates for short serum half-life with very tight binding to the receptor.

Otvos L Jr, Vetter SW, Koladia M, Knappe D, Schmidt R, Ostorhazi E, Kovalszky I, Bionda N, Cudic P, Surmacz E, Wade JD, Hoffmann R.

Amino Acids. 2014 Apr;46(4):873-82. doi: 10.1007/s00726-013-1650-6. Epub 2013 Dec 24.

PMID:
24366600
8.

Leptin and adiponectin: emerging therapeutic targets in breast cancer.

Surmacz E.

J Mammary Gland Biol Neoplasia. 2013 Dec;18(3-4):321-32. doi: 10.1007/s10911-013-9302-8. Epub 2013 Oct 18. Review.

PMID:
24136336
9.

Exploring leptin antagonism in ophthalmic cell models.

Scolaro L, Parrino C, Coroniti R, Otvos L Jr, Surmacz E.

PLoS One. 2013 Oct 3;8(10):e76437. doi: 10.1371/journal.pone.0076437. eCollection 2013.

10.

Designer peptide antagonist of the leptin receptor with peripheral antineoplastic activity.

Beccari S, Kovalszky I, Wade JD, Otvos L Jr, Surmacz E.

Peptides. 2013 Jun;44:127-34. doi: 10.1016/j.peptides.2013.03.027. Epub 2013 Apr 6.

PMID:
23567149
11.

Effects of PPARγ agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells.

Terrasi M, Bazan V, Caruso S, Insalaco L, Amodeo V, Fanale D, Corsini LR, Contaldo C, Mercanti A, Fiorio E, Lo Re G, Cicero G, Surmacz E, Russo A.

J Cell Physiol. 2013 Jun;228(6):1368-74. doi: 10.1002/jcp.24295.

PMID:
23254958
12.

Metformin inhibits leptin-induced growth and migration of glioblastoma cells.

Ferla R, Haspinger E, Surmacz E.

Oncol Lett. 2012 Nov;4(5):1077-1081. Epub 2012 Aug 3.

13.

Design and development of a peptide-based adiponectin receptor agonist for cancer treatment.

Otvos L Jr, Haspinger E, La Russa F, Maspero F, Graziano P, Kovalszky I, Lovas S, Nama K, Hoffmann R, Knappe D, Cassone M, Wade J, Surmacz E.

BMC Biotechnol. 2011 Oct 5;11:90. doi: 10.1186/1472-6750-11-90.

14.

Targeting the leptin receptor: a potential new mode of treatment for breast cancer.

Otvos L Jr, Surmacz E.

Expert Rev Anticancer Ther. 2011 Aug;11(8):1147-50. doi: 10.1586/era.11.109. No abstract available.

PMID:
21916566
15.

Glioblastoma-derived leptin induces tube formation and growth of endothelial cells: comparison with VEGF effects.

Ferla R, Bonomi M, Otvos L Jr, Surmacz E.

BMC Cancer. 2011 Jul 19;11:303. doi: 10.1186/1471-2407-11-303.

16.

Toward understanding the role of leptin and leptin receptor antagonism in preclinical models of rheumatoid arthritis.

Otvos L Jr, Shao WH, Vanniasinghe AS, Amon MA, Holub MC, Kovalszky I, Wade JD, Doll M, Cohen PL, Manolios N, Surmacz E.

Peptides. 2011 Aug;32(8):1567-74. doi: 10.1016/j.peptides.2011.06.015. Epub 2011 Jun 23.

PMID:
21723351
17.

Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer.

Otvos L Jr, Kovalszky I, Riolfi M, Ferla R, Olah J, Sztodola A, Nama K, Molino A, Piubello Q, Wade JD, Surmacz E.

Eur J Cancer. 2011 Jul;47(10):1578-84. doi: 10.1016/j.ejca.2011.01.018. Epub 2011 Feb 23.

PMID:
21353530
18.

Leptin-based therapeutics.

Scolaro L, Cassone M, Kolaczynski JW, Otvos L Jr, Surmacz E.

Expert Rev Endocrinol Metab. 2010 Nov;5(6):875-889. doi: 10.1586/eem.10.61.

PMID:
30780830
19.

Obesity hormone leptin induces growth and interferes with the cytotoxic effects of 5-fluorouracil in colorectal tumor stem cells.

Bartucci M, Svensson S, Ricci-Vitiani L, Dattilo R, Biffoni M, Signore M, Ferla R, De Maria R, Surmacz E.

Endocr Relat Cancer. 2010 Aug 16;17(3):823-33. doi: 10.1677/ERC-10-0083. Print 2010 Sep.

PMID:
20603394
20.

Relationships between hypoxia markers and the leptin system, estrogen receptors in human primary and metastatic breast cancer: effects of preoperative chemotherapy.

Koda M, Kanczuga-Koda L, Sulkowska M, Surmacz E, Sulkowski S.

BMC Cancer. 2010 Jun 22;10:320. doi: 10.1186/1471-2407-10-320.

21.

Peptide-based leptin receptor antagonists for cancer treatment and appetite regulation.

Otvos L Jr, Kovalszky I, Scolaro L, Sztodola A, Olah J, Cassone M, Knappe D, Hoffmann R, Lovas S, Hatfield MP, Beko G, Zhang S, Wade JD, Surmacz E.

Biopolymers. 2011;96(2):117-25. doi: 10.1002/bip.21377.

PMID:
20564005
22.

Leptin-based glycopeptide induces weight loss and simultaneously restores fertility in animal models.

Kovalszky I, Surmacz E, Scolaro L, Cassone M, Ferla R, Sztodola A, Olah J, Hatfield MP, Lovas S, Otvos L Jr.

Diabetes Obes Metab. 2010 May;12(5):393-402. doi: 10.1111/j.1463-1326.2009.01170.x.

PMID:
20415687
23.

miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells.

Cascio S, D'Andrea A, Ferla R, Surmacz E, Gulotta E, Amodeo V, Bazan V, Gebbia N, Russo A.

J Cell Physiol. 2010 Jul;224(1):242-9. doi: 10.1002/jcp.22126.

PMID:
20232316
24.

Leptin and its receptor are overexpressed in brain tumors and correlate with the degree of malignancy.

Riolfi M, Ferla R, Del Valle L, Piña-Oviedo S, Scolaro L, Micciolo R, Guidi M, Terrasi M, Cetto GL, Surmacz E.

Brain Pathol. 2010 Mar;20(2):481-9. doi: 10.1111/j.1750-3639.2009.00323.x. Epub 2009 Aug 6.

25.

Expression of angiogenic regulators, VEGF and leptin, is regulated by the EGF/PI3K/STAT3 pathway in colorectal cancer cells.

Cascio S, Ferla R, D'Andrea A, Gerbino A, Bazan V, Surmacz E, Russo A.

J Cell Physiol. 2009 Oct;221(1):189-94. doi: 10.1002/jcp.21843.

PMID:
19492417
26.

Functional analysis of the -2548G/A leptin gene polymorphism in breast cancer cells.

Terrasi M, Fiorio E, Mercanti A, Koda M, Moncada CA, Sulkowski S, Merali S, Russo A, Surmacz E.

Int J Cancer. 2009 Sep 1;125(5):1038-44. doi: 10.1002/ijc.24372.

27.

Agonists and partial antagonists acting on the leptin--leptin receptor interface.

Otvos L Jr, Cassone M, Terrasi M, Cascio S, Mateo GD, Knappe D, Hoffmann R, Cudic P, Wade JD, Surmacz E.

Adv Exp Med Biol. 2009;611:497-8. No abstract available.

PMID:
19400282
28.

Estrogen receptor beta-mediated nuclear interaction between IRS-1 and Rad51 inhibits homologous recombination directed DNA repair in medulloblastoma.

Urbanska K, Pannizzo P, Lassak A, Gualco E, Surmacz E, Croul S, Del Valle L, Khalili K, Reiss K.

J Cell Physiol. 2009 May;219(2):392-401. doi: 10.1002/jcp.21683.

29.

Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysis.

Fiorio E, Mercanti A, Terrasi M, Micciolo R, Remo A, Auriemma A, Molino A, Parolin V, Di Stefano B, Bonetti F, Giordano A, Cetto GL, Surmacz E.

BMC Cancer. 2008 Oct 22;8:305. doi: 10.1186/1471-2407-8-305.

30.

Insulin-dependent leptin expression in breast cancer cells.

Bartella V, Cascio S, Fiorio E, Auriemma A, Russo A, Surmacz E.

Cancer Res. 2008 Jun 15;68(12):4919-27. doi: 10.1158/0008-5472.CAN-08-0642.

31.

Development of a pharmacologically improved peptide agonist of the leptin receptor.

Otvos L Jr, Terrasi M, Cascio S, Cassone M, Abbadessa G, De Pascali F, Scolaro L, Knappe D, Stawikowski M, Cudic P, Wade JD, Hoffmann R, Surmacz E.

Biochim Biophys Acta. 2008 Oct;1783(10):1745-54. doi: 10.1016/j.bbamcr.2008.05.007. Epub 2008 May 21.

32.

Insulin receptor substrate 1 modulates the transcriptional activity and the stability of androgen receptor in breast cancer cells.

Lanzino M, Garofalo C, Morelli C, Le Pera M, Casaburi I, McPhaul MJ, Surmacz E, Andò S, Sisci D.

Breast Cancer Res Treat. 2009 May;115(2):297-306. doi: 10.1007/s10549-008-0079-1. Epub 2008 Jun 4.

PMID:
18521741
33.

Is BRCA1-5083del19, identified in breast cancer patients of Sicilian origin, a Calabrian founder mutation?

Russo A, Calò V, Bruno L, Schirò V, Agnese V, Cascio S, Foddai E, Fanale D, Rizzo S, Di Gaudio F, Gulotta E, Surmacz E, Di Fede G, Bazan V.

Breast Cancer Res Treat. 2009 Jan;113(1):67-70. doi: 10.1007/s10549-008-9906-7. Epub 2008 Jan 29.

PMID:
18228134
34.

4843delC of the BRCA1 gene is a possible founder mutation in Southern Italy (Sicily).

Russo A, Calò V, Augello C, Bruno L, Agnese V, Schirò V, Barbera F, Cascio S, Foddai E, Badalamenti G, Intrivici C, Cajozzo M, Gulotta G, Surmacz E, Colucci G, Gebbia N, Bazan V.

Ann Oncol. 2007 Jun;18 Suppl 6:vi99-102.

35.

Founder mutations in BRCA1 and BRCA2 genes.

Ferla R, Calò V, Cascio S, Rinaldi G, Badalamenti G, Carreca I, Surmacz E, Colucci G, Bazan V, Russo A.

Ann Oncol. 2007 Jun;18 Suppl 6:vi93-8. Review.

36.

The estrogen receptor alpha:insulin receptor substrate 1 complex in breast cancer: structure-function relationships.

Sisci D, Morelli C, Cascio S, Lanzino M, Garofalo C, Reiss K, Garcia M, Russo A, Andò S, Surmacz E.

Ann Oncol. 2007 Jun;18 Suppl 6:vi81-5.

PMID:
17591841
37.

Expression of the obesity hormone leptin and its receptor correlates with hypoxia-inducible factor-1 alpha in human colorectal cancer.

Koda M, Sulkowska M, Kanczuga-Koda L, Cascio S, Colucci G, Russo A, Surmacz E, Sulkowski S.

Ann Oncol. 2007 Jun;18 Suppl 6:vi116-9.

PMID:
17591803
38.

Overexpression of the obesity hormone leptin in human colorectal cancer.

Koda M, Sulkowska M, Kanczuga-Koda L, Surmacz E, Sulkowski S.

J Clin Pathol. 2007 Aug;60(8):902-6.

39.

Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1alpha.

Cascio S, Bartella V, Auriemma A, Johannes GJ, Russo A, Giordano A, Surmacz E.

Oncogene. 2008 Jan 17;27(4):540-7. Epub 2007 Jul 23.

PMID:
17653093
40.

Crosstalk between IGF signaling and steroid hormone receptors in breast cancer.

Sisci D, Surmacz E.

Curr Pharm Des. 2007;13(7):705-17. Review.

PMID:
17346185
41.

Obesity hormone leptin: a new target in breast cancer?

Surmacz E.

Breast Cancer Res. 2007;9(1):301. Review.

42.

BRCA1 genetic testing in 106 breast and ovarian cancer families from Southern Italy (Sicily): a mutation analyses.

Russo A, Calò V, Agnese V, Bruno L, Corsale S, Augello C, Gargano G, Barbera F, Cascio S, Intrivici C, Rinaldi G, Gulotta G, Macaluso M, Surmacz E, Giordano A, Gebbia N, Bazan V.

Breast Cancer Res Treat. 2007 Nov;105(3):267-76. Epub 2007 Jan 13.

PMID:
17221156
43.

Insulin-like growth factor 1 differentially regulates estrogen receptor-dependent transcription at estrogen response element and AP-1 sites in breast cancer cells.

Cascio S, Bartella V, Garofalo C, Russo A, Giordano A, Surmacz E.

J Biol Chem. 2007 Feb 9;282(6):3498-506. Epub 2006 Dec 13.

44.

Expression of nuclear insulin receptor substrate 1 in breast cancer.

Sisci D, Morelli C, Garofalo C, Romeo F, Morabito L, Casaburi F, Middea E, Cascio S, Brunelli E, Andò S, Surmacz E.

J Clin Pathol. 2007 Jun;60(6):633-41. Epub 2006 Aug 1.

45.

Nuclear and cytoplasmic interaction of pRb2/p130 and ER-beta in MCF-7 breast cancer cells.

Macaluso M, Montanari M, Noto PB, Gregorio V, Surmacz E, Giordano A.

Ann Oncol. 2006 Jun;17 Suppl 7:vii27-9.

PMID:
16760287
46.

Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli.

Garofalo C, Koda M, Cascio S, Sulkowska M, Kanczuga-Koda L, Golaszewska J, Russo A, Sulkowski S, Surmacz E.

Clin Cancer Res. 2006 Mar 1;12(5):1447-53.

47.

TP53 and p16INK4A, but not H-KI-Ras, are involved in tumorigenesis and progression of pleomorphic adenomas.

Augello C, Gregorio V, Bazan V, Cammareri P, Agnese V, Cascio S, Corsale S, Calò V, Gullo A, Passantino R, Gargano G, Bruno L, Rinaldi G, Morello V, Gerbino A, Tomasino RM, Macaluso M, Surmacz E, Russo A.

J Cell Physiol. 2006 Jun;207(3):654-9.

PMID:
16447252
48.

RNAi-mediated silencing of insulin receptor substrate 1 (IRS-1) enhances tamoxifen-induced cell death in MCF-7 breast cancer cells.

Cesarone G, Garofalo C, Abrams MT, Igoucheva O, Alexeev V, Yoon K, Surmacz E, Wickstrom E.

J Cell Biochem. 2006 May 15;98(2):440-50.

PMID:
16440325
49.

Leptin and cancer.

Garofalo C, Surmacz E.

J Cell Physiol. 2006 Apr;207(1):12-22. Review.

PMID:
16110483
50.

Functional significance of type 1 insulin-like growth factor-mediated nuclear translocation of the insulin receptor substrate-1 and beta-catenin.

Chen J, Wu A, Sun H, Drakas R, Garofalo C, Cascio S, Surmacz E, Baserga R.

J Biol Chem. 2005 Aug 19;280(33):29912-20. Epub 2005 Jun 20.

Supplemental Content

Loading ...
Support Center